 |
|
           |
| Access educational resources for your patients to help them better understand and manage their CML. Learn more > |
| Since its development, Glivec® has been a cornerstone of therapy for CML patients. Learn more > |
Novartis' Commitment to the Global CML Community
The development of the first molecularly targeted therapy for the treatment of CML epitomizes the commitment of Novartis Oncology to consistently discovering, developing, and producing broadly available novel therapies that improve the lives of patients with cancer. Novartis' commitment also extends to offering comprehensive educational and support services such as CML Alliance to the physicians and patients who use our products. |
|
See European Summary of Product Characteristics Glivec® 100 mg film coated tablets (PDF) Glivec® 400 mg film coated tablets (PDF) Glivec® 50 mg capsules, hard (PDF) Glivec® 100 mg capsules, hard (PDF)
About CML Alliance | Treating CML | Targeted Therapies and CML Contact | Site Map | Privacy |
© 2010 Novartis AG |